We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App




New Hematology Analyzer Brings High-Standard Reticulocyte Analysis to a Compact Platform

By LabMedica International staff writers
Posted on 03 Mar 2014
A new, reliable, easy-to-use hematology analyzer with integrated PC eliminates manual methods to enhance laboratory productivity while maintaining standardization.

Horiba Medical division of Horiba UK (Northhampton, UK) now offers the new "Pentra XLR compact 5 part DIFF" hematology analyzer, incorporating full reticulocyte parameters to facilitate the investigation and diagnosis of hemopoiesis and anemia. More...
As the latest addition to the Pentra family, the XLR brings Horiba’s gold standard reticulocyte technology with STAT capabilities to a smaller platform. This makes it well suited for space-restricted laboratories or those with a smaller workload, without compromising on quality.

The new, reliable, easy-to-use analyzer with integrated PC eliminates manual methods to enhance laboratory productivity and ensure standardization of reticulocyte count. The Pentra XLR’s large capacity autoloader and ability to process 80 samples per hour, combined with auto rerun, Customized Dilution Ratio (CDR) and automatic validation, all enable a hands-off approach. Users can thus dedicate valuable time to results analysis and more specialised needs.

Providing a high degree of flexibility, the new Pentra XLR has a microsampling system requiring only 53 µl of blood for FBC and 35 µl for full reticulocyte analysis, making it well suited for pediatric or other small samples. The reticulocyte channel utilizes Thiazole Orange technology, providing a full maturity profile in addition to a highly accurate reticulocyte count. It is also compatible with ABX Pentra ML data management, facilitating simple integration into existing systems.
The new Pentra XLR is built on the same proven reticulocyte technology as Horiba’s higher throughput Pentra analyzers, ensuring quality and full compatibility of results and reagents. With three quality control levels for all parameters, this robust and reliable platform also provides complete data traceability on-board and integrated validation, thus enhancing peace of mind also for the user.

“The Pentra XLR enhances laboratory productivity, flexibility and quality, adding value to any hematology laboratory,” said Cleve Wright, Horiba UK; “By incorporating full reticulocyte analytical capabilities, the Pentra XLR delivers high quality detailed analysis for highly accurate patient diagnosis on a compact platform.”

Related Links:

Horiba Medical



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Steam Sterilizer
Hi Vac II Line
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.